M
Motohiko Sano
Researcher at Hoshi University
Publications - 14
Citations - 376
Motohiko Sano is an academic researcher from Hoshi University. The author has contributed to research in topics: Cancer & Chemotherapy. The author has an hindex of 5, co-authored 10 publications receiving 338 citations. Previous affiliations of Motohiko Sano include Saitama Medical University.
Papers
More filters
Journal ArticleDOI
The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
Takashi Kawaguchi,Kanako Azuma,Motohiko Sano,Soan Kim,Yosuke Kawahara,Yoko Sano,Tomohide Shimodaira,Keiichiro Ishibashi,Tempei Miyaji,Ethan Basch,Takuhiro Yamaguchi +10 more
TL;DR: There is underestimation in the assessment of adverse events in Japan, and that the Japanese version of the PRO-CTCAE had acceptable reliability and validity for common and clinically important symptoms.
Journal ArticleDOI
Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study
TL;DR: These data are insufficient to conclude with any certainty that the administration of Ca/Mg is not neuroprotective; however, the administration may not have any influence on antitumor activity and the blood concentration profile of platinum in patients receiving oxaliplatin-based chemotherapy.
Journal ArticleDOI
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer
Naohiko Inoue,Hideyuki Ishida,Motohiko Sano,Tohru Kishino,Norimichi Okada,Kensuke Kumamoto,Keiichiro Ishibashi +6 more
TL;DR: It is suggested that the concomitant use of NCI-CTCAE and DEB-NTC would be useful to maintain oxaliplatin-based chemotherapy at higher quality.
Journal ArticleDOI
In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs.
Yosuke Iijima,Kenjiro Bandow,Motohiko Sano,Shunsuke Hino,Takahiro Kaneko,Norio Horie,Hiroshi Sakagami +6 more
TL;DR: Among 12 classical anticancer drugs, taxanes and gemsitabine showed the highest tumor-specificity (TS) and potency-selectivity expression (PSE) values, whereas platinum analogs showed the least TS value.
Journal ArticleDOI
Development of Newly Synthesized Chromone Derivatives with High Tumor Specificity against Human Oral Squamous Cell Carcinoma.
Yoshiaki Sugita,Koichi Takao,Yoshihiro Uesawa,Junko Nagai,Yosuke Iijima,Motohiko Sano,Hiroshi Sakagami +6 more
TL;DR: In this article, a comprehensive investigation with human malignant and nonmalignant cells demonstrated that derivatives of chromone, back-bone structure of flavonoid, showed much higher tumor specificity as compared with three major polyphenols in the natural kingdom, such as lignin-carbohydrate complex, tannin, and flavonoids.